PAS-004, a next-generation macrocyclic MEK inhibitor, is advancing through Phase 1/1b trials for NF1 and advanced cancers, showing promising safety, efficacy, and pharmacokinetics. It targets large unmet needs in NF1-PN and NF1-CN, with strong intellectual property and financial positioning.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.